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Systematic reviews and meta-analyses have become in-
creasingly important in health care. Clinicians read them
to keep up to date with their field [1,2], and they are often
used as a starting point for developing clinical practice
guidelines. Granting agencies may require a systematic
review to ensure there is justification for further research
[3], and some health care journals are moving in this
direction [4]. As with all research, the value of a system-
atic review depends on what was done, what was found,
and the clarity of reporting. As with other publications,
the reporting quality of systematic reviews varies, limiting
readers’ ability to assess the strengths and weaknesses of
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doi: 10.1016/j.jclinepi.2009.06.005Several early studies evaluated the quality of review
reports. In 1987, Mulrow examined 50 review articles pub-
lished in four leading medical journals in 1985 and 1986
and found that none met all eight explicit scientific criteria,
such as a quality assessment of included studies [5]. In
1987, Sacks and colleagues [6] evaluated the adequacy of
reporting of 83 meta-analyses on 23 characteristics in six
domains. Reporting was generally poor; between one and
14 characteristics were adequately reported (mean5 7.7;
standard deviation5 2.7). A 1996 update of this study
found little improvement [7].
In 1996, to address the suboptimal reporting of meta-
analyses, an international group developed a guidance
called the QUOROM Statement (QUality Of Reporting
Of Meta-analyses), which focused on the reporting of
meta-analyses of randomized controlled trials [8]. In this
article, we summarize a revision of these guidelines,
renamed PRISMA (Preferred Reporting Items for System-
atic reviews and Meta-Analyses), which have been updated
to address several conceptual and practical advances in the
science of systematic reviews (Box 1).2. Terminology
The terminology used to describe a systematic review
and meta-analysis has evolved over time. One reason for
changing the name from QUOROM to PRISMA was
the desire to encompass both systematic reviews and
meta-analyses. We have adopted the definitions used by
the Cochrane Collaboration [9]. A systematic review is a re-
view of a clearly formulated question that uses systematic
and explicit methods to identify, select, and critically ap-
praise relevant research, and to collect and analyze data
from the studies that are included in the review. StatisticalInc. All rights reserved.
Box 1 Conceptual Issues in the Evolution from
QUOROM to PRISMA
Completing a Systematic Review Is an Itera-
tive Process
The conduct of a systematic review depends heavily on
the scope and quality of included studies: thus system-
atic reviewers may need to modify their original review
protocol during its conduct. Any systematic review re-
porting guideline should recommend that such changes
can be reported and explained without suggesting that
they are inappropriate. The PRISMA Statement (Items
5, 11, 16, and 23) acknowledges this iterative process.
Aside from Cochrane reviews, all of which should have
a protocol, only about 10% of systematic reviewers
report working from a protocol [22].Without a protocol
that is publicly accessible, it is difficult to judge
between appropriate and inappropriate modifications.
Conduct and Reporting Research Are Distinct
Concepts
This distinction is, however, less straightforward for
systematic reviews than for assessments of the
reporting of an individual study, because the reporting
and conduct of systematic reviews are, by nature,
closely intertwined. For example, the failure of a sys-
tematic review to report the assessment of the risk of
bias in included studies may be seen as a marker of
poor conduct, given the importance of this activity
in the systematic review process [37].
Study-Level Versus Outcome-Level Assess-
ment of Risk of Bias
For studies included in a systematic review, a thorough
assessment of the risk of bias requires both a ‘‘study-
level’’ assessment (e.g., adequacy of allocation con-
cealment) and, for some features, a newer approach
called ‘‘outcome-level’’ assessment. An outcome-
level assessment involves evaluating the reliability
and validity of the data for each important outcome
by determining the methods used to assess them in
each individual study [38]. The quality of evidence
may differ across outcomes, even within a study, such
as between a primary efficacy outcome, which is
likely to be very carefully and systematically mea-
sured, and the assessment of serious harms [39],
which may rely on spontaneous reports by investiga-
tors. This information should be reported to allow an
explicit assessment of the extent to which an estimate
of effect is correct [38].
Continued. Importance of Reporting Biases
Different types of reporting biases may hamper the
conduct and interpretation of systematic reviews.
Selective reporting of complete studies (e.g., publica-
tion bias) [28] as well as the more recently empirically
demonstrated ‘‘outcome reporting bias’’ within indi-
vidual studies [40,41] should be considered by authors
when conducting a systematic review and reporting its
results. Though the implications of these biases on the
conduct and reporting of systematic reviews them-
selves are unclear, some previous research has identi-
fied that selective outcome reporting may occur also in
the context of systematic reviews [42].
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lyze and summarize the results of the included studies.
Meta-analysis refers to the use of statistical techniques in
a systematic review to integrate the results of included
studies.3. Developing the PRISMA Statement
A three-day meeting was held in Ottawa, Canada, in
June 2005 with 29 participants, including review authors,
methodologists, clinicians, medical editors, and a consumer.
The objective of the Ottawa meeting was to revise and ex-
pand the QUOROM checklist and flow diagram, as needed.
The executive committee completed the following tasks,
prior to the meeting: a systematic review of studies exam-
ining the quality of reporting of systematic reviews, and
a comprehensive literature search to identify methodologi-
cal and other articles that might inform the meeting, espe-
cially in relation to modifying checklist items. An
international survey of review authors, consumers, and
groups commissioning or using systematic reviews and
meta-analyses was completed, including the International
Network of Agencies for Health Technology Assessment
(INAHTA) and the Guidelines International Network
(GIN). The survey aimed to ascertain views of QUOROM,
including the merits of the existing checklist items. The
results of these activities were presented during the meeting
and are summarized on the PRISMA Web site (http://
www.prisma-statement.org/).
Only items deemed essential were retained or added to
the checklist. Some additional items are nevertheless desir-
able, and review authors should include these, if relevant
[10]. For example, it is useful to indicate whether the sys-
tematic review is an update [11] of a previous review,
and to describe any changes in procedures from those
described in the original protocol.
Shortly after the meeting a draft of the PRISMA check-
list was circulated to the group, including those invited to
Table 1
Checklist of items to include when reporting a systematic review or meta-analysis.
Section/Topic # Checklist Item Reported on Page #
TITLE
Title 1 Identify the report as a systematic review, meta-analysis, or both.
ABSTRACT
Structured summary 2 Provide a structured summary including, as applicable: background; objectives;
data sources; study eligibility criteria, participants, and interventions;
study appraisal and synthesis methods; results; limitations; conclusions and
implications of key findings; systematic review registration number.
INTRODUCTION
Rationale 3 Describe the rationale for the review in the context of what is already known.
Objectives 4 Provide an explicit statement of questions being addressed with reference to
participants, interventions, comparisons, outcomes, and study design (PICOS).
METHODS
Protocol
and registration
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address),
and, if available, provide registration information including registration number.
Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report
characteristics (e.g., years considered, language, publication status) used
as criteria for eligibility, giving rationale.
Information sources 7 Describe all information sources (e.g., databases with dates of coverage, contact with
study authors to identify additional studies) in the search and date last searched.
Search 8 Present full electronic search strategy for at least one database, including any limits
used, such that it could be repeated.
Study selection 9 State the process for selecting studies (i.e., screening, eligibility, included in
systematic review, and, if applicable, included in the meta-analysis).
Data collection process 10 Describe method of data extraction from reports (e.g., piloted forms, independently,
in duplicate) and any processes for obtaining and confirming data from investigators.
Data items 11 List and define all variables for which data were sought (e.g., PICOS, funding sources)
and any assumptions and simplifications made.
Risk of bias in
individual studies
12 Describe methods used for assessing risk of bias of individual studies
(including specification of whether this was done at the study or outcome level), and how
this information is to be used in any data synthesis.
Summary measures 13 State the principal summary measures (e.g., risk ratio, difference in means).
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done,
including measures of consistency (e.g., I2) for each meta-analysis.
Risk of bias
across studies
15 Specify any assessment of risk of bias that may affect the cumulative evidence
(e.g., publication bias, selective reporting within studies).
Additional analyses 16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-
regression), if done, indicating which were pre-specified.
RESULTS
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review,
with reasons for exclusions at each stage, ideally with a flow diagram.
Study characteristics 18 For each study, present characteristics for which data were extracted
(e.g., study size, PICOS, follow-up period) and provide the citations.
Risk of bias
within studies
19 Present data on risk of bias of each study and, if available, any outcome-level assessment
(see Item 12).
Results of
individual studies
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary
data for each intervention group and (b) effect estimates and confidence intervals, ideally
with a forest plot.
Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals
and measures of consistency.
Risk of bias across studies 22 Present results of any assessment of risk of bias across studies (see Item 15).
Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses,
meta-regression [see Item 16]).
DISCUSSION
Summary
of evidence
24 Summarize the main findings including the strength of evidence for each main
outcome; consider their relevance to key groups (e.g., health care providers, users,
and policy makers).
Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review level
(e.g., incomplete retrieval of identified research, reporting bias).
Conclusions 26 Provide a general interpretation of the results in the context of other evidence,
and implications for future research.
FUNDING
Funding 27 Describe sources of funding for the systematic review and other support
(e.g., supply of data); role of funders for the systematic review.
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ated containing comments and revisions from each respon-
dent, and the checklist was subsequently revised 11 times.
The group approved the checklist, flow diagram, and this
summary paper.
Although no direct evidence was found to support
retaining or adding some items, evidence from other
domains was believed to be relevant. For example, Item
5 asks authors to provide registration information about
the systematic review, including a registration number,
if available. Although systematic review registration is
not yet widely available [12,13], the participating journals
of the International Committee of Medical Journal Editors
(ICMJE) [14] now require all clinical trials to be regis-
tered in an effort to increase transparency and account-
ability [15]. Those aspects are also likely to benefit
systematic reviewers, possibly reducing the risk of an
excessive number of reviews addressing the same ques-
tion [16,17] and providing greater transparency when
updating systematic reviews.4. The PRISMA Statement
The PRISMA Statement consists of a 27-item checklist
(Table 1; see also Text S1 for a downloadable Word tem-
plate for researchers to re-use) and a four-phase flow# of records identified
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Fig. 1. Flow of information through the difdiagram (Figure 1; see also Figure S1 for a downloadable
Word template for researchers to re-use). The aim of the
PRISMA Statement is to help authors improve the reporting
of systematic reviews and meta-analyses. We have focused
on randomized trials, but PRISMA can also be used as a ba-
sis for reporting systematic reviews of other types of
research, particularly evaluations of interventions. PRISMA
may also be useful for critical appraisal of published
systematic reviews. However, the PRISMA checklist is
not a quality assessment instrument to gauge the quality
of a systematic review.5. From QUOROM to PRISMA
The new PRISMA checklist differs in several respects
from the QUOROM checklist, and the substantive specific
changes are highlighted in Table 2. Generally, the PRISMA
checklist ‘‘decouples’’ several items present in the QUOR-
OM checklist and, where applicable, several checklist items
are linked to improve consistency across the systematic
review report.
The flow diagram has also been modified. Before includ-
ing studies and providing reasons for excluding others, the
review team must first search the literature. This search re-
sults in records. Once these records have been screened and
eligibility criteria applied, a smaller number of articles will# of additional records
identified through other
sources
 duplicates removed
screened # of records
excluded
t articles
eligibility
included
 synthesis
# of full-text
articles
excluded, with
reasons
included
tative
ta-analysis)
ferent phases of a systematic review.
Table 2
Substantive specific changes between the QUOROM checklist and the PRISMA checklist (a tick indicates the presence of the topic in QUOROM or
PRISMA).
Section/Topic Item QUOROM PRISMA Comment
Abstract O O QUOROM and PRISMA ask authors to report an abstract. However,
PRISMA is not specific about format.
Introduction Objective O This new item (4) addresses the explicit question the review
addresses using the PICO reporting system (which describes the participants,
interventions, comparisons, and outcome(s) of the systematic review),
together with the specification of the type of study design (PICOS); the item
is linked to Items 6, 11, and 18 of the checklist.
Methods Protocol O This new item (5) asks authors to report whether the review has
a protocol and if so how it can be accessed.
Methods Search O O Although reporting the search is present in both QUOROM and
PRISMA checklists, PRISMA asks authors to provide a full description
of at least one electronic search strategy (Item 8). Without such information
it is impossible to repeat the authors’ search.
Methods Assessment of risk of
bias in included studies
O O Renamed from ‘‘quality assessment’’ in QUOROM. This item (12)
is linked with reporting this information in the results (Item 19).
The new concept of ‘‘outcome-level’’ assessment has been introduced.
Methods Assessment of risk
of bias across studies
O This new item (15) asks authors to describe any assessments of
risk of bias in the review, such as selective reporting within the included studies.
This item is linked with reporting this information in the results (Item 22).
Discussion O O Although both QUOROM and PRISMA checklists address the discussion
section, PRISMA devotes three items (24e26) to the discussion. In PRISMA
the main types of limitations are explicitly stated and their discussion required.
Funding O This new item (27) asks authors to provide information on any sources of funding
for the systematic review.
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(or larger) than the number of studies, because articles
may report on multiple studies and results from a particular
study may be published in several articles. To capture this
information, the PRISMA flow diagram now requests infor-
mation on these phases of the review process.6. Endorsement
The PRISMA Statement should replace the QUOROM
Statement for those journals that have endorsed QUOROM.
We hope that other journals will support PRISMA; they
can do so by registering on the PRISMA Web site. To
underscore to authors, and others, the importance of transpar-
ent reporting of systematic reviews,we encourage supporting
journals to reference the PRISMA Statement and include the
PRISMAWeb address in their Instructions to Authors. We
also invite editorial organizations to consider endorsing
PRISMA and encourage authors to adhere to its principles.7. The PRISMA Explanation and Elaboration Paper
In addition to the PRISMA Statement, a supporting
Explanation and Elaboration document has been produced
[18] following the style used for other reporting guidelines
[19e21]. The process of completing this document
included developing a large database of exemplars to high-
light how best to report each checklist item, and identifying
a comprehensive evidence base to support the inclusion ofeach checklist item. The Explanation and Elaboration
document was completed after several face to face meet-
ings and numerous iterations among several meeting partic-
ipants, after which it was shared with the whole group for
additional revisions and final approval. Finally, the group
formed a dissemination subcommittee to help disseminate
and implement PRISMA.8. Discussion
The quality of reporting of systematic reviews is still not
optimal [22e27]. In a recent review of 300 systematic
reviews, few authors reported assessing possible publication
bias [22], even though there is overwhelming evidence both
for its existence [28] and its impact on the results of system-
atic reviews [29]. Even when the possibility of publication
bias is assessed, there is no guarantee that systematic re-
viewers have assessed or interpreted it appropriately [30].Al-
though the absence of reporting such an assessment does not
necessarily indicate that it was not done, reporting an assess-
ment of possible publication bias is likely to be a marker of
the thoroughness of the conduct of the systematic review.
Several approaches have been developed to conduct sys-
tematic reviews on a broader array of questions. For exam-
ple, systematic reviews are now conducted to investigate
cost-effectiveness [31], diagnostic [32] or prognostic ques-
tions [33], genetic associations [34], and policy making
[35]. The general concepts and topics covered by PRISMA
are all relevant to any systematic review, not just those
whose objective is to summarize the benefits and harms
1011D. Moher et al. / Journal of Clinical Epidemiology 62 (2009) 1006e1012of a health care intervention. However, some modifications
of the checklist items or flow diagram will be necessary in
particular circumstances. For example, assessing the risk of
bias is a key concept, but the items used to assess this in
a diagnostic review are likely to focus on issues such as
the spectrum of patients and the verification of disease
status, which differ from reviews of interventions. The flow
diagram will also need adjustments when reporting
individual patient data meta-analysis [36].
We have developed an explanatory document [18] to
increase the usefulness of PRISMA. For each checklist
item, this document contains an example of good reporting,
a rationale for its inclusion, and supporting evidence,
including references, whenever possible. We believe this
document will also serve as a useful resource for those
teaching systematic review methodology. We encourage
journals to include reference to the explanatory document
in their Instructions to Authors.
Like any evidence-based endeavor, PRISMA is a living
document. To this end we invite readers to comment on the
revised version, particularly the new checklist and flow
diagram, through the PRISMA Web site. We will use such
information to inform PRISMA’s continued development.Acknowledgments
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